Mazdutide Demonstrates Efficacy in Managing Type 2 Diabetes in Chinese Patients
A phase 3 trial in Chinese adults with type 2 diabetes showed that mazdutide, a dual GCGR/GLP-1R agonist, significantly improved glycemic control and promoted weight loss compared to placebo, with a favorable safety profile.